Smith & Nephew SNATS, Inc. (SNN) Stake Cut by Jarislowsky Fraser Ltd

Jarislowsky Fraser Ltd lowered its position in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) by 1.2% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 404,476 shares of the medical equipment provider’s stock after selling 5,109 shares during the period. Jarislowsky Fraser Ltd owned approximately 0.09% of Smith & Nephew SNATS worth $14,095,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in SNN. Citadel Advisors LLC raised its position in Smith & Nephew SNATS by 456.2% in the first quarter. Citadel Advisors LLC now owns 405,596 shares of the medical equipment provider’s stock valued at $12,545,000 after buying an additional 332,669 shares during the period. Karp Capital Management Corp acquired a new position in Smith & Nephew SNATS during the first quarter valued at about $10,007,000. Cambiar Investors LLC raised its position in Smith & Nephew SNATS by 6.2% in the first quarter. Cambiar Investors LLC now owns 5,143,756 shares of the medical equipment provider’s stock valued at $159,096,000 after buying an additional 301,213 shares during the period. Bank of America Corp DE raised its position in Smith & Nephew SNATS by 10.9% in the first quarter. Bank of America Corp DE now owns 1,526,036 shares of the medical equipment provider’s stock valued at $47,200,000 after buying an additional 149,672 shares during the period. Finally, Nuance Investments LLC raised its position in Smith & Nephew SNATS by 6.5% in the first quarter. Nuance Investments LLC now owns 2,147,255 shares of the medical equipment provider’s stock valued at $66,415,000 after buying an additional 131,388 shares during the period. 7.08% of the stock is owned by institutional investors and hedge funds.

Smith & Nephew SNATS, Inc. (NYSE:SNN) traded down 0.45% during mid-day trading on Friday, hitting $35.38. 566,364 shares of the stock traded hands. The stock has a market capitalization of $15.49 billion, a PE ratio of 18.01 and a beta of 0.77. The company has a 50 day moving average price of $34.79 and a 200-day moving average price of $32.65. Smith & Nephew SNATS, Inc. has a one year low of $26.97 and a one year high of $35.85.

ILLEGAL ACTIVITY WARNING: “[[title]]” was originally reported by [[site]] and is the property of of [[site]]. If you are reading this piece on another domain, it was illegally stolen and republished in violation of US and international copyright legislation. The original version of this piece can be accessed at [[permalink]].

Several research analysts recently issued reports on the stock. BidaskClub lowered shares of Smith & Nephew SNATS from a “buy” rating to a “hold” rating in a research report on Tuesday. Zacks Investment Research raised shares of Smith & Nephew SNATS from a “hold” rating to a “buy” rating and set a $38.00 price target for the company in a research report on Tuesday, July 11th. Seven research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Smith & Nephew SNATS currently has a consensus rating of “Hold” and an average target price of $38.00.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices.